Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy: A multicenter phase III study
Vito Lorusso, Giuseppe Colucci(Roche (Switzerland)), Saverio Cinieri(Ospedale A. Perrino), Vittorio Gebbia(Università degli Studi di Enna Kore), Luciana Petrucelli(Ospedale Vito Fazzi), Salvatore Pisconti(Ospedale SS. Annunziata), Mariangela Ciccarese(Ospedale Vito Fazzi), Evaristo Maiello(Casa Sollievo della Sofferenza), Alessio Gambino(Ospedale Vito Fazzi), Laura Isabella Lupo(Ospedale Vito Fazzi), Francesco Giotta(Istituto Tumori Bari), S. Del Prete, G. FILIPELLI, R. Forcignanò(Ospedale Vito Fazzi), S. Romito(Ospedali Riuniti di Foggia), Silvana Leo(Ospedale Vito Fazzi), Ferdinando Riccardi(Ospedale Antonio Cardarelli), V. Saracino(Ospedale Vito Fazzi), Roberto Bordonaro(Ospedale Garibaldi)
Cited by 26
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial
|JNCI Journal of the National Cancer Institute|2003|795
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234